Peptides vs. Steroids: A Lifter's Guide to Long-Term Health Risks

It's Not 'If', It's 'What'

Many lifters reading this are already weighing performance drugs, whether for a bigger total or a leaner physique. For them, the practical question is often which compounds, not whether. That choice can affect health for years after the competition or the personal record.

For decades, the main option was anabolic-androgenic steroids (AAS), and users accepted shutdown, liver strain and cardiac stress as the cost. Peptides work through different mechanisms, so their risk profile is different too. Different isn't the same as safe: most of these peptides have far less human data than steroids, and missing data is a risk in its own right.

Your Heart: The Price of Power

Heart risk is where the gap between the two classes is best documented.

With steroids, two problems stand out. First, pathological left ventricular hypertrophy (LVH). This isn't the healthy "athlete's heart" that comes from years of hard training. It's a stiffening and thickening of the heart muscle that makes it a less efficient pump and raises the risk of arrhythmias and heart failure later on. Second, the lipid profile worsens: HDL (the "good" cholesterol that helps clear plaque) tends to fall while LDL (the "bad" cholesterol that builds it) rises, which speeds atherosclerosis. A 2017 study in Circulation compared 86 experienced male weightlifters with at least 2 years of cumulative AAS use against 54 lifters who didn't use them. The AAS users had weaker heart pumping (average ejection fraction 52% vs 63%) and more coronary artery plaque, and plaque rose with lifetime duration of use. It was a cross-sectional study, so it shows an association rather than proof of cause, but it measured the hearts and arteries directly.

Growth hormone secretagogues such as CJC-1295 and Ipamorelin act on the pituitary, not the androgen receptor, so there's no reason to expect androgen-type heart thickening or HDL loss from them. Calling them heart-safe overstates what's known, though. No trial has followed secretagogue users long enough to measure heart outcomes, and the short-term data include warning signs:

• CJC-1295: FDA's December 2024 advisory committee review summarized 2006 trials in healthy adults that reported vasodilatory reactions, raised heart rate, dizziness and low blood pressure. FDA also described an unpublished Phase 2 trial in people with HIV lipodystrophy that was stopped after a participant had a fatal heart attack 2 hours after his 11th weekly dose; the attending physician blamed undiagnosed coronary artery disease. As of October 2026, FDA's compounding safety list cites increased heart rate and systemic vasodilatory reactions for CJC-1295.
• Heart failure: A Phase IIb trial of MK-677 (an oral drug, not a peptide, that acts on the same receptor as ipamorelin) at 25 mg/day in 123 elderly hip-fracture patients was stopped early for a congestive heart failure signal. Nobody knows whether that applies to younger, healthy users.
• Blood sugar: In a 2-year trial in 65 healthy older adults, MK-677 raised fasting glucose by about 5 mg/dL and lowered insulin sensitivity. In ipamorelin's Phase 2 trial after abdominal surgery, the ipamorelin group had more high blood sugar at discharge than placebo. That trial missed its primary endpoint, and development stopped.

On lipids, the same MK-677 trial found a small drop in LDL and no change in HDL. Water retention, the most common complaint in user reports, can also nudge blood pressure up. So the androgen-type damage seen with AAS is absent, while the cardiovascular and metabolic effects of raising growth hormone for years have barely been studied.

The Liver Question: Toxin vs. Signal

Liver damage from oral steroids is one of the best-known risks among lifters, and here the two classes really do differ.

The usual culprits are the 17-alpha-alkylated (17aa) oral steroids such as Dianabol, Anadrol and Winstrol. That chemical modification helps the molecule survive its first pass through the liver, but it comes at a cost. A 2026 review in Frontiers in Endocrinology describes liver effects ranging from symptomless rises in enzymes such as ALT and AST to cholestatic jaundice (blocked bile flow), liver adenomas and, rarely, liver cancer. Injectable steroids are much less hepatotoxic, but the liver is still the main site of steroid metabolism.

Peptides are chains of amino acids, and the body breaks them down by proteolysis, much as it handles dietary protein. They don't go through the same toxic metabolic processes in the liver. No liver signal has been reported for BPC-157, TB-500 or the GH secretagogues, but that partly reflects how little anyone has looked. A systematic review of BPC-157 covering studies through mid-2024 found 35 preclinical studies, 1 clinical study and no clinical safety data. As of October 2026, FDA says it has found no human exposure data for the TB-500 fragment. Gray-market vials add another unknown: the same BPC-157 review flags contamination and unregulated manufacturing as possible sources of harm.

Endocrine System: Shutdown vs. Stimulation

If cardiac risk is the first reason to be wary of steroids, HPTA shutdown is a close second. When external androgens enter the body, the brain senses plenty of testosterone and shuts down its own production through the hypothalamic-pituitary-testicular axis (HPTA).

This is why coming off a steroid cycle is hard for many users. Natural production is offline, and testosterone stays low until the body (hopefully) restarts the system. Many users follow a Post-Cycle Therapy (PCT) protocol with prescription drugs such as clomiphene (Clomid) or tamoxifen (Nolvadex), used off-label, to try to restart the HPTA. The 2026 Frontiers review notes that short or single cycles are often followed by partial or full recovery, while prolonged exposure is linked to low testosterone that can persist for months or years. Some former users end up on prescription testosterone replacement therapy (TRT). Sperm production is suppressed during use as well.

Peptides, specifically the GH secretagogues, work on the opposite principle: stimulation, not replacement. A GHRH analog like Sermorelin or CJC-1295 without DAC tells the pituitary to release a pulse of growth hormone. A GHRP like GHRP-2 or Ipamorelin amplifies that pulse. They don't suppress testosterone production, which is a real advantage over AAS. They aren't hormonally neutral, though: human studies show GHRP-2 also raises cortisol and prolactin, MK-677 raised cortisol in its 2-year trial, and in a 2006 CJC-1295 trial IGF-1 rose above the normal range at the highest dose. Many users cycle these compounds on and off; our article on peptide cycling strategies covers the schedules people describe.

The Cancer Risk: Separating Signal from Noise

This is where the peptide conversation requires nuance. The fear with compounds that increase growth hormone and Insulin-like Growth Factor 1 (IGF-1) is a theoretical risk of cancer.

There's no evidence that GH secretagogues or IGF-1 analogues start cancers. The concern is that IGF-1 is a strong pro-survival and pro-growth signal. That's useful for muscle cells and unhelpful for a pre-existing, undiagnosed cancerous cell. The worry is that raising IGF-1 could speed the growth of a tumor that's already there. The evidence comes largely from associative data in acromegaly patients (who have pathologically high GH/IGF-1 for decades) and lab studies. BPC-157 raises a related theoretical question: in animal studies it boosts pathways involved in cell growth and angiogenesis, and no human study has looked at tumor risk.

Nobody has measured the cancer risk of a 12-week ipamorelin course in people, and no trial is large or long enough to do so. The risk is probably small, but it can't be quantified. Certain steroids have been associated with specific cancers, such as prostate cancer, through their androgenic action, though that link is still debated. For a healthy person with no family history of cancer, many users judge the peptide risk acceptable. For someone with a pre-existing condition or high genetic risk, it deserves more weight.

A Different Class of Risk

Neither class is safe. The risks differ in kind and in how well they're documented.

Traditional steroids carry well-documented, high-probability side effects: testosterone suppression in nearly every user, heart and lipid damage that grows with lifetime use, and liver risk with oral 17aa compounds. The damage is predictable and often cumulative.

GH-axis peptides avoid testosterone suppression and the androgen effects on lipids and the liver, but they bring the blood-sugar and cardiovascular risks described above, most of them seen only in short or small studies. Repair peptides have too little human data to describe a long-term risk profile at all: on the site's evidence scale, BPC-157 is emerging (three small, uncontrolled human pilots) and TB-500 is preliminary.

There are legal and sporting consequences too. As of October 2026, WADA prohibits every peptide named on this page at all times, and our legal implications article covers the gray-market side. For a compound-by-compound look at long-term risks, see the overview of long-term peptide health effects.

Comparison table